International Journal of Pharmaceutical and Bio-Medical Science

ISSN(print): 2767-827X, ISSN(online): 2767-830X

Volume 03 Issue 12 December 2023

Page No: 728-733

DOI: https://doi.org/10.47191/ijpbms/v3-i12-05, Impact Factor: 6.858

Viral Hemorrhagic Fever

Hind T. Hamad¹, Yaseen K. Mohammed², Abeer Saleh Hasan³

¹ Department of Medical Laboratory Technologies, Al-Dour Technical Institute, Northern Technical University, Saladin, Iraq. ² General Directorate of Education-Balad Education Department, Saladin, Iraq.

³College of health and medical technique - Aldour- department of optic, Northern Technical University, Saladin, Iraq.

ABSTRACT

ARTICLE DETAILS

Most viruses implicated in these diseases require vectors for transmission to humans, most are transmitted by arthropods or rodent-borne infections, and due to the zoonotic nature of these diseases, these diseases are generally confined to endemic areas where their hosts live. Symptoms of the hemorrhagic fever virus include fatigue, aches, cough, fever, shortness of breath, and eye redness. Given that viral genome detection is the best tool for diagnosis, however, blood sampling requires personal medical training and involves important risks for the patient as well as for personal healthcare. Sampling may therefore be by non-invasive methods (eg, saliva or urine), as well as multiplex PCR, lateral flow assays, and non-invasive sampling, including saliva and urine. It was found that there are many immune indicators related to the hemorrhagic fever virus, including protein C and D-dimer, which were found to increase when infected with hemorrhagic fever. As for inflammatory cytokines, they were found to play an important role in causing infection with the hemorrhagic fever virus, including interleukin 6, interferon gamma, as well as About tumor necrosis factor.

 KEYWORDS: Viral Hemorrhagic fever, Pathogenesis of viral hemorrhagic, C-Reactive protein,
 Available on:

 Interleukin.
 https://ijpbms.com/

INTRODUCTION

Viruses are described as units that comprise genetic factors made of RNA or DNA and encapsulated in a protein envelope known as capsid. It is the smallest of the organic systems, as it covers each the genetic traits essential for its replication within the intruding mobile ⁽¹⁾. Viruses spread in many approaches through exclusive paths named transmission paths, as human viruses are transmitted thru coughing or sneezing from an infected person to a healthful man or woman ⁽²⁾, and other forms of viruses have appeared, which can be referred to as hemorrhagic fever viruses (HFVs), which are a group of zoonotic diseases acute respiratory infections Due to seven special families of viruses that contaminate human and animal ⁽³⁾.

Hemorrhagic fever viruses (HFVs) are highly contagious RNA viruses characterized by mild to severe symptoms and may lead to multi-organ failure and death ^(3,4). Hemorrhagic fever viruses represent a Predominant global public fitness situation because of their high occurrence and mortality fees ^(5,6). Most of the viruses implicated in these illnesses require

vectors to be transmitted to humans, most of which are transmitted by arthropods or rodents, and due to the zoonotic nature of those diseases, these diseases are typically restrained to endemic regions wherein their hosts stay ⁽⁷⁾.

VHFs are branded by irregular organization and injury to blood vessels ⁽³⁾. Although they share some clinical manifestations, their orbital and organoid cells, As well as the molecular devices fundamental pathogenesis range relying on the causative agent ⁽⁷⁾. However, they all Goal the cells chargeable for starting up the antiviral reaction, inflicting a delay in the immune response. Moreover, this postponement in the immune response leads to patient with VHFs having high viral infections and immunosuppression which could result in a flash-surprise-like syndrome in which inflammatory mediators play a main function in infection with these viruses ^(8,9). As in Figure (1), which exemplifies the greatest significant inflammatory mediators in viral hemorrhagic fevers.




Figure (1) illustrates the most important inflammatory mediators in viral hemorrhagic fevers ⁽¹⁰⁾.

The pathogenesis of severe viral hemorrhagic fever leads to:

(A) - Antigen-presenting cells (APCs) it gives an immature phenotype with low expression of co-stimulatory molecules and coffee production of kind I interferon (IFN-I), resulting in impaired activation of natural killer cells and T cells leading to immunosuppression Generalized, leading to uncontrollability.

(B)- During infection, monocyte and macrophage produce high levels of inflammatory cytokines which reason endothelial and platelet start and T-cell apoptosis.

(C)- APC infection transmits hemorrhagic fever viruses (HFVs) to the lymph nodes and other structures, producing them to spread and thus lead to infection of certain organs, including the liver and adrenal glands, which leads to high liver function and low clotting factors⁽¹¹⁾.




Fig (2) Overview of VHF causing viruses (12)

Symptoms of viral hemorrhagic fever:	4 Aches
Common symptoms of the disease may be:	Fever
4 Tiredness	Coughing cough
729 Volume 03 Issue 12 December	Corresponding Author: Hind T. Hamad

Viral Hemorrhagic Fever

- **4** Abdominal pain.
- Shortness of breath or difficulty breathing
- Heeding gums or epistaxis.
- Vomiting
- Sorethrout sore throat
- \blacksquare Diarrhea ⁽¹³⁾.

Diagnosis of infection with hemorrhagic fever virus

The PCR technique is more than molecular diagnostics to identify viral diseases including viral pathogen screening ⁽¹⁴⁾.

There are several method for diagnosing hemorrhagic fever virus, including the immunoassay technique and enzyme test. This method usages a solid matrix covered with a exact gene (oligonucleotide) or antigen from the viruses producing the viral acid. Then obtain a DNA sample. The signal is likened by the intensity of the positive control and a diagnosis is complete. Microarrays of viruses producing hemorrhagic fevers have tall specificity and diagnostic compassion ⁽¹⁵⁾. An ELISA is also available to detect IgM and IgG antibodies.




Fig 3:- Diagnostic methods for viral hemorrhagic fevers (16)

Treatments for hemorrhagic fever:

There are vaccines such as Hantavax, which have been test in patient with hemorrhagic fever and have shown high seroconversion rates and low hospitalizations ⁽¹⁷⁾. And The use of plasma as another treatment to reduce the chances of wound infection and reduce the death rate ⁽¹⁸⁾. In addition, he received Inmazeb, a combination of three monoclonal antibody against two protein for treatment ⁽¹⁹⁾.

Relationship between Immunological variables and hemorrhagic fever

C-reactive protein CRP and hemorrhagic fever

C-reactive protein It is one in every of the intense inflammatory protein, which arise when contamination or inflammation happens, as it is synthesize or produce in hepatic cell, in adding to numerous cell, along with lymphocyte, , macrophage ⁽²⁰⁾. As exposed in Figure (4).




Figure (4) Structure of C-reactive protein (21)

The course of CRP in this case series indicates that a decrease in CRP level is associated with better survival while a gradual rise may predict a poor outcome, furthermore, Yilmaz and his group and Buyuktuna and his group reported that an elevated CRP level in patients with hemorrhagic fever was reported as a predictive indicator of infection ⁽²²⁾.

D-dimer and hemorrhagic fever

Represents a small molecular protein, resulting from the decomposition of fibrin, as a biomarker detailing clotting molecules, the coagulation dimer level rises, the coagulation dimer level rises, the coagulation D dimer level rises, the coagulation D dimer level rises, the patient's pneumonia rises, and its height increases ⁽²³⁾.

D-dimer is one of the diagnostic indicators for hemorrhagic fever, which is an acute febrile clinical syndrome associated with headache, myalgia, arthralgia, rash, Leukopenia, hemorrhagic manifestations (24). Although these symptoms are consistent with those of the affected person defined in this case file, many of them are nonspecific and may be found in some of not unusual infections, making early analysis difficult. especially in African regions such as Nigeria and other countries where it is high. rates of malaria, patients with this symptom are often misdiagnosed ⁽²⁵⁾.

Interleukins and hemorrhagic fever

Interleukins are proteins that stimulate the immune system in the body to do its work in resisting infections. The body's interleukins are formed in white blood cells, which are cells that work to destroy harmful bacteria and other harmful bodies that enter the body. Internally, Leukin means white proteins that are secreted from white blood cells and work on them. Interleukin regulates cell growth, differentiation, and motility, and is specifically significant in stimulating immune response along with inflammation ⁽²⁶⁾. Pathogens implicated in viral hemorrhagic fevers can multiply inside phagocytes and dendritic cells, permitting rapid proliferation within the host. Macrophages are inspired to release cytokines and chemokines, which reason improved vascular permeability and blood clotting repute. These viruses also can cause mechanisms that lead to blood clotting within the blood vessels. Infected stem cells are weakened, and loss of their proper feature can cause lymphoid apoptosis (27). Interleukin-6 is a multifunctional cytokinesis. It plays a key position as a mediator of many inflammatory responses in the acute section. These consist of inflammatory cells, activation of lymphocytes, and stimulation of hepatocytes to manufacture acute-phase proteins. Interleukin-6 is low in normal conditions and its levels in serum. It cannot be detected in the case of weak inflammation, and its increase contributes to many diseases, especially in people of advanced age, such as lymphoma, osteoporosis, and hemorrhagic fever ⁽²⁸⁾. The upregulated look of anti-inflammatory cytokines e.g. IL-6 and IL-10 promotes dengue and hemorrhagic fever virus replication and leads to disease progression (29).

REFERENCES

- Ahmed, Tariq Younis, Al-Hilali Louay Abdel Ali. Biochemistry. The second part. University of Mosul; 2010.
- II. Vignesh Mariappan, Pooja Pratheesh, Lokesh Shanmugam, S.R. Rao, Agieshkumar Balakrishna

Viral Hemorrhagic Fever

Pillai. Viral hemorrhagic fever: Molecular pathogenesis and current trends of disease management-an update. Current Research in Virological Science. 2, 2021, 100009.

- III. Schnittler, H.-J., and Feldmann, H. Viral hemorrhagic fever--a vascular disease? Thromb. Haemost. 2003; 89: 967–972.
- IV. Basler, C. F. Molecular pathogenesis of viral hemorrhagic fever. Semin. Immunopathol. 2017; 39:551–561.
- V. Abir, M. H., Rahman, T., Das, A., Etu, S. N., Nafiz, I. H., Rakib, A., et al. Pathogenicity and virulence of Marburg virus. Virulence. 2022; 13, 609–633.
- VI. Hickman, M. R., Saunders, D. L., Bigger, C. A., Kane, C. D., and Iversen, P. L. The development of broad-spectrum antiviral medical countermeasures to treat viral hemorrhagic fevers caused by natural or weaponized virus infections. PLoS Negl. Trop. Dis. 2022. 16:e0010220. doi: 10.1371/journal.pntd.0010220.
- VII. Paessler, S., and Walker, D. H. Pathogenesis of the viral hemorrhagic fevers. Annu. Rev. Pathol. Mech. Dis. 2013; 8, 411–440.
- VIII. Reynard, S., Russier, M., Fizet, A., Carnec, X., and Baize, S. Exonuclease domain of the Lassa Virus nucleoprotein is critical to avoid RIG-I signaling and to inhibit the innate immune response. J. Virol. 2014; 88, 13923–13927.
 - IX. Woolsey, C., Cross, R. W., Agans, K. N., Borisevich, V., Deer, D. J., Geisbert, J. B., et al. A highly attenuated Vesiculovax vaccine rapidly protects nonhuman primates against lethal Marburg virus challenge. PLoS Negl. Trop. Dis. 2022; 16:e0010433. doi: 10.1371/journal.pntd.0010433.
 - X. Lizdany Flórez-Álvarez ,Edmarcia Elisa de Souza , Viviane Fongaro Botosso , Danielle Bruna Leal de Oliveira .et al. Hemorrhagic fever viruses: Pathogenesis, therapeutics, and emerging and reemerging potential. Institute of Biomedical Science. Volume 13 2022 | https://doi.org/10.3389/fmicb.2022.1040093
- XI. Asogun DA, Günther S, Akpede GO, Ihekweazu C, Zumla A. Lassa Fever: Epidemiology, Clinical Features, Diagnosis, Management and Prevention. Infect Dis Clin North Am. 2019 Dec;33(4):933-951.
- XII. Asogun DA, Günther S, Akpede GO, Ihekweazu C, Zumla A. Lassa Fever: Epidemiology, Clinical Features, Diagnosis, Management and Prevention. Infect Dis Clin North Am. 2019 Dec;33(4):933-951.
- XIII. Drifa Belhadi, Majda El Baied, Guillaume Mulier, Denis Malvy, France Mentré, Cédric Laouénan .The number of cases, mortality and treatments of viral hemorrhagic fevers: A systematic review. Belhadi D, El Baied M, Mulier G, Malvy D, Mentré F,

Laouénan C . The number of cases, mortality and treatments of viral hemorrhagic fevers: A systematic review. PLoS Negl Trop Dis . 2022; 16(10): e0010889. doi:10.1371/journal.pntd.0010889.

- XIV. Asogun DA, Günther S, Akpede GO, Ihekweazu C, Zumla A. Lassa Fever: Epidemiology, Clinical Features, Diagnosis, Management and Prevention. Infect Dis Clin North Am. 2019 Dec;33(4):933-951.
- XV. Bente DA, Forrester NL, Watts DM, McAuley AJ, Whitehouse CA, Bray M. Crimean-Congo hemorrhagic fever: history, epidemiology, pathogenesis, clinical syndrome and genetic diversity. Antiviral Res. 2013 Oct;100(1):159-89.
- XVI. Hidalgo J, Richards GA, Jiménez JIS, Baker T, Amin P. Viral hemorrhagic fever in the tropics: Report from the task force on tropical diseases by the World Federation of Societies of Intensive and Critical Care Medicine. J Crit Care. 2017 Dec;42:366-372.
- XVII. Jung, J., Ko, S.-J., Oh, H. S., Moon, S. M., Song, J.-W., and Huh, K. Protective effectiveness of inactivated hantavirus vaccine against hemorrhagic fever with renal syndrome. J. Infect. Dis. 2018; 217, 1417–1420.
- XVIII. Winkler, A. M., and Koepsell, S. A. The use of convalescent plasma to treat emerging infectious diseases. Curr. Opin. Hematol. 2015; 22, 521–526.
- XIX. FDA (2022). FDA Approves First Treatment for Ebola Virus | FDA. Available at: https://www.fda.gov/news-events/pressannouncements/fda-approves-first-treatment-ebolavirus [Accessed August 2, 2022].
- XX. Luan YY, Yao YM. The clinical significance and potential role of C-reactive protein in chronic inflammatory and neurodegenerative diseases. Front Immunol .2018; 9: 1302–1308.
- XXI. structure. Chemical structure of human c-reactive protein (crp). increased blood CanStock, canstockphoto,CRP. Available at: https://www.canstockphoto.com/human-c-reactiveprotein-crp-chemical-11386366.html (Accessed: 22 June 2021).
- XXII. Büyüktuna SA, Doğan HO, Unlusavuran M, Bakir M. An evaluation of the different biomarkers to discriminate bleeding in Crimean-Congo Hemorrhagic Fever. Ticks Tick Borne Dis. 2019;10:997–1002.
- XXIII. Querol-Ribelles JM, Tenias JM, Grau E, Querol-Borras JM, Climent JL, Gomez E, et al. Plasma ddimer levels correlate with outcomes in patients with community-acquired pneumonia. Chest. 2004;126: 1087–1092. pmid:15486368.

Viral Hemorrhagic Fever

- XXIV. Hadinegoro SRS. The revised WHO dengue case classification: Does the system need to be modified? Paediatr Int Child Health. 2012 May;32(Suppl 1):33–8.
- XXV. Fagbami AH, Onoja AB. Dengue haemorrhagic fever: An emerging disease in Nigeria, West Africa. J Infect Public Health. 2018 Nov-Dec;11(6):757–762.
- XXVI. Xu M, Mizoguchi I, Morishima N, Chiba Y, Mizuguchi J, Yoshimoto T. Regulation of antitumor immune responses by the IL-12 family cytokines, IL-12, IL-23, and IL-27. Clinical and Developmental immunology;2010.65.56789.
- XXVII. Commins S.P, Borish L, Steinke J.W. "Immunologic messenger molecules : Cytokines , interferons , and chemokines", J. Allergy Clin . Immunol .2010; Vol . 125, PP. S53-S72 .
- XXVIII. William B, Ershler MD. "interleukin-6 A cytokine for Gerontologists. Journal of the American Geriatrics society.2012; 41(2):176-181.
- XXIX. Chareonsirisuthigul T, Kalayanarooj S, Ubol S. Dengue virus (DENV) antibody-dependent enhancement of infection upregulates the production of anti-inflammatory cytokines, but suppresses anti-DENV free radical and pro-inflammatory cytokine production, in THP-1 cells. J Gen Virol 2007; 88:365–375.